James Bensler, MD
Cardiovascular Disease · Jackson, MSNPI 1457591570
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $52,325 of the $64,173 with a category attached, or 81.5%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 65.6% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $28,178 and has fallen 92.2% since, to $2,196 in 2025. Among cardiovascular disease clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 274 payments — averaging $234.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$42K
- Pfizer$9K
- E.r. Squibb & Sons, L.L.C.$6K
- Medtronic$4K
- Abbott$646
- Atricure, Inc.$608
- plus $2K from 18 others
What the payments were for
- Consulting fees$8001%
- Speaking & faculty fees$52,32582%
- Travel & lodging$3,3255%
- Food & beverage$7,69012%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 55 | $42,116 |
| Pfizer | 29 | $9,424 |
| E.r. Squibb & Sons, L.L.C. | 19 | $5,574 |
| Medtronic(2 entities) | 67 | $3,827 |
| Abbott | 12 | $646 |
| Atricure, Inc. | 9 | $608 |
| Boehringer Ingelheim | 18 | $438 |
| Boston Scientific | 13 | $334 |
| Novartis | 18 | $222 |
| Biotronik Inc. | 6 | $166 |
| Kestra Medical Technology Services, Inc. | 2 | $161 |
| Lantheus Medical Imaging, Inc. | 1 | $120 |
| ZOLL Medical Corporation | 1 | $115 |
| Johnson & Johnson | 4 | $77 |
| Cvrx, Inc. | 1 | $54 |
| Irhythm Technologies, Inc. | 3 | $43 |
| Akcea Therapeutics, Inc. | 3 | $42 |
| Amgen | 3 | $42 |
| Biosense Webster, Inc. | 2 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $30 |
| Merck | 2 | $28 |
| AstraZeneca | 2 | $25 |
| Cardiva Medical, Inc. | 1 | $25 |
| Davol Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$40,964
- ELIQUIS$14,073
- EVERA MRI XT DR SURESCAN$1,079
- AURORA EV-ICD MRI SURESCAN$422
- Micra$375
- AMPLATZER AMULET$320
- Visia AF$167
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$148
- ENSITE$146
- SYNERGY ABLATION SYSTEM$144
- AZURE XT DR MRI SURESCAN$143
- Assure WCD$141
- Compia MRI$127
- COBALT DR MRI SURESCAN$125
- JARDIANCE$125
- Definity$120
- Cobalt$119
- Defibrillator$115
- Arctic Front$103
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, MODELS$101
How this compares
$64,173 in reported general payments places this provider in the 95th percentile of 144 cardiovascular disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 745 | $579,525 |
| XareltoRivaroxaban | 255 | $220,480 |
| EntrestoSacubitril/Valsartan | 200 | $181,689 |
| JardianceEmpagliflozin | 88 | $77,166 |
| FarxigaDapagliflozin Propanediol | 39 | $34,298 |
| MultaqDronedarone Hcl | 15 | $12,557 |
| Metoprolol Succinate | 666 | $10,234 |
| Ranolazine ErRanolazine | 124 | $9,625 |
| Dofetilide | 46 | $4,974 |
| Carvedilol | 533 | $3,471 |
| Amiodarone Hcl | 90 | $3,203 |
| Spironolactone | 343 | $2,241 |
| Propafenone Hcl ErPropafenone Hcl | 13 | $2,224 |
| Digoxin | 156 | $1,844 |
| Flecainide Acetate | 87 | $1,809 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $9,424 | $579,525745 claims |
| Johnson & JohnsonXarelto | $77 | $220,480255 claims |
| NovartisEntresto | $222 | $181,689200 claims |
| Boehringer IngelheimJardiance | $438 | $77,16688 claims |
| AstraZenecaFarxiga | $25 | $34,29839 claims |
| Sanofi-aventis U.S. LLCMultaq | $30 | $12,55715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 144 cardiovascular disease providers in Mississippi.
Other cardiovascular disease in Jackson
- Donny StokesJackson$207K
- Michael HallJackson$54K
- Tahsin QarqishJackson$39K
- Christopher LatourJackson$33K
- Varun SardarJackson$31K
- Olurotimi BaderoJackson$20K
- Michael PaymentJackson$16K
- James HaysJackson$16K
- Douglas HarkinsJackson$14K
- Aditya SabharwalJackson$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.